Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc (ARCT) Historical Volatility
ARCT's 30 day historical volatility is 119.00%, in the 92nd percentile of readings over the past year. This is a high percentile, meaning Arcturus Therapeutics Holdings Inc shares have swung far more than usual. ARCT's 30 day implied volatility sits at 203.47%, with an IV Rank of 93.25%, leaving IV 84.47 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 13, 2026.
Read more
Tracking ARCT historical volatility helps you see how much Arcturus Therapeutics Holdings Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ARCT's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ARCT 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ARCT's 30 day historical volatility, or ARCT HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ARCT's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 13, 2026
As of Nov 13, 2026
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →